Michael Liu on why he thinks Cogstate $COGZF is a great business wrapped in a special situation play

Episode Summary

Executive Summary: The episode profiles Cogstate, an Australian microcap that provides computerized cognitive tests for Alzheimer’s clinical trials and related screening. Guest Michael Liu argues the selloff after a failed takeover bid created an attractive entry point: Cogstate is the dominant player in a growing field, benefits from rising Alzheimer’s R&D and decentralized trials, and could see more revenue from post-approval studies and consumer screening. The main debate is whether the valuation is cheap enough despite lumpy bookings and near-term delays.

Main Topics: Cogstate’s business model and market position (Priority: 5/5): Cogstate sells computerized cognitive testing used mainly in Alzheimer’s drug trials. It is portrayed as the dominant provider, far larger than the next competitor, with deep ties to major pharma and CRO partners. Why computerized testing beats paper-and-pencil methods (Priority: 5/5): The discussion explains that Cogstate’s tests are validated, standardized, hard to game through practice effects, and better suited for remote/decentralized trials than legacy paper tests. Alzheimer’s R&D as the core growth driver (Priority: 5/5): The guests argue that recent approvals and successful readouts have reopened pharma investment in Alzheimer’s, increasing trial activity and creating a long runway for Cogstate bookings and revenue. Special situation: failed takeover and stock selloff (Priority: 4/5): The stock fell sharply after leaked acquisition talks reportedly broke down over price, creating a special-situation setup that exposed the business at a lower valuation. Valuation and booking-based lens (Priority: 4/5): They emphasize bookings over near-term revenue because contract timing can be lumpy. On that basis, the stock is described as trading at the low end of its historical range despite improving growth prospects. Management, insider buying, and buyback (Priority: 4/5): Management is presented as aligned and conservative, with insider purchases and a new buyback program seen as signals of confidence after the post-deal collapse. Potential takeout candidates and strategic value (Priority: 3/5): The likely bidders are discussed as existing channel partners or CROs seeking deeper exposure to CNS/Alzheimer’s, making Cogstate a logical strategic acquisition target.

Key Arguments: Cogstate is the leading computerized cognitive testing platform for Alzheimer’s trials and has durable relationships with major pharma, making it hard to displace. The company benefits from switching costs, validation history, and FDA/industry precedent, so competitors or big pharma are unlikely to replace it with in-house tools. Legacy paper-and-pencil tests are less standardized, more error-prone, and poorly suited to remote trials, which supports continued adoption of Cogstate’s platform. Recent Alzheimer’s drug successes are expected to expand R&D, not end it, because approved drugs open the door to follow-on mechanisms, confirmatory studies, and post-marketing monitoring. The stock decline was driven by a failed acquisition rather than business deterioration, and the underlying fundamentals remain strong. Bookings are the best indicator of future revenue; current delays mainly shift revenue timing rather than destroy demand. Management’s insider buying and buyback suggest conviction that the stock is undervalued after the selloff. A strategic buyer could still emerge from Cogstate’s channel partners, who want exposure to CNS and Alzheimer’s research. Cogstate’s consumer screening license with Eisai could broaden the addressable market beyond clinical trials.

Data Points: Stock decline from highs: about 40% - Guest said Cogstate fell sharply from earlier highs after the failed takeover news and related technical events. Comparable takeover spike and drop: stock ran from $2 to $2.40 then fell to about $1.20-$1.30 - Described the prelude to the halted trading and post-deal selloff in the Australian market. Market cap: around $175 million - Host estimated Cogstate’s U.S. market cap at roughly this level. Enterprise value: just under $150 million - Host estimated EV using the U.S. ticker around this level. Clinical trials revenue: $40-45 million - Guest used this figure to estimate current sales and valuation on a revenue basis. Trailing bookings: about $60 million - Guest said trailing bookings are around this level, making bookings the best leading indicator. Expected bookings: about $80 million - Guest said the company can do about this much in the current year. Historical bookings multiple: 2x to 4x bookings - Guest said Cogstate has historically traded within this valuation range. Current valuation on bookings: about 2x to 2.5x bookings - Guest argued the stock is near the low end of its historical range. Current valuation on sales: about 3x sales - Guest cited this as low for a business with strong margins and growth potential. Scalable EBIT margin: 20% to 25% - Guest said Cogstate has demonstrated this margin potential and still guides toward it long term. Market share in computerized cognitive tests: about 13% - Guest said Cogstate’s share is roughly this level, and that computerized tests are still a minority of the total market. Computerized vs paper tests market mix: roughly 10%-20% computerized and 80%-90% paper-and-pencil - Discussion framed Cogstate as dominant within a still-small computerized segment. Eisai ownership: 10% stake - Guest said Eisai bought this equity position in Cogstate a few years ago. Eisai license agreement: $50 million - Guest described the license to bring Cogstate’s test into direct-to-consumer screening. Daily treatment economics example: $10 test vs $20,000 drug - Used to illustrate why pharma would want broader screening and diagnosis. Buyback program: $13 million - Guest said Cogstate announced its first share buyback. Insider purchases: $100,000 CEO; $75,000 chairman - Management bought stock after the selloff. Chairman ownership: about 20% - Guest said Martin Meyer owns a large stake and has supported financing over the years. CEO ownership: about 5% - Guest said Brad O’Connor owns a meaningful personal stake. Historic IPO price: 50 cents per share in 2004 - Guest contrasted the long-term performance from IPO to the current price. Peak price before selloff: about $2.40 - Guest referenced the stock’s rise before the acquisition collapse. Phase-three timing: late September readout - Guest said a key Alzheimer’s drug readout drove optimism and stock strength earlier in the year.

Pivotal Quotes: "you’re left with sort of this great business at the lowest valuation that it’s been in several years" — Michael Liu: Summary of why the post-selloff setup looks attractive. "Big pharma is very picky about what they put into a clinical trial" — Michael Liu: Explaining why validated endpoints and precedent matter so much in Alzheimer’s trials. "we’ll be unapologetic about seeking to maximize returns for our shareholders" — Host quoting management: Illustrating management’s stance after the failed acquisition and the stock drop.

Implications: If Alzheimer’s R&D keeps expanding, Cogstate could see sustained bookings growth, more consumer screening demand, and possible strategic interest from CROs or pharma-backed buyers. The main risk is lumpy timing and whether near-term delays are only temporary.